Back to my company list

Oxford Drug Design

The AI engine Fit Assessment

Beta

InhibOx leverages advanced machine learning technologies and pattern discovery methods to expand therapeutic options, particularly in the development of novel antibiotics.

Blurb

Oxford Drug Design focuses on developing and delivering services and technologies in computer-aided drug discovery.

HQ Location

Oxford (United Kingdom)

Founded

2001

Employees

1 - 10

Total funding raised

$11.26M

Last Funding Event

Convertible Note, $2.74M, May 19, 2022

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Discovery Optimization
  • Drug Repurposing

Operator of a biotechnology company intended to develop therapies to treat drug-resistant infections. The company's methods offer the application of new technologies to drive computer-aided drug discovery from target identification through preclinical and formulation studies and against cancer and other challenging diseases with high unmet medical needs seeking good patient outcomes, enabling healthcare professionals to access new antibiotics to treat drug-resistant bacterial infections.